Shares of Moderna Inc. MRNA advanced 1.72% to $40.27 Tuesday, on what proved to be an all-around positive trading session for ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

A pediatric vaccine for respiratory syncytial virus (RSV) is proving to be elusive, according to news from the U.S. Food and ...

Moderna Inc. closed $130.88 short of its 52-week high ($170.47), which the company reached on May 24th.

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on ...

Most years, I find one or two stocks among the biggest losers that I think are worth buying. This year there are three — ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

Investing.com -- Argus downgraded Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to "hold" from "buy," on declining sales of its COVID-19 vaccine and limited near-term growth prospects. We recently compiled ...